Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HER2+
•
HR+
What adjuvant chemotherapy would you recommend for a postmenopausal woman with history of porphyria and newly diagnosed T2 N0 triple positive breast cancer?
Related Questions
What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
What are your top takeaways in Medical Oncology from SABCS 2024?
How do you reconcile data from the PATINA trial and DESTINY-Breast09 with respect to CDK4/6 inhibitor maintenance in metastatic ER+ HER2+ breast cancer?
How does the safety profile of Dato-DXd influence its use in patients with comorbidities or frailty compared to standard chemotherapy?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?
Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/HER2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?
What supportive care measures do you prioritize to manage or prevent toxicity in patients receiving Dato-DXd?
